April 11, 2013 — A new oral diabetes drug is expected to arrive on pharmacy shelves in the U.S. this week. Many people predict that Invokana (canagliflozin), approved by the FDA in March, will be a brisk seller. That's partly because it treats type 2
Type 2 Diabetes
Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine. A 24-Week, Randomized, Placebo-Controlled Study (GETGOAL-DUO-1)
Context: Women with a history of gestational diabetes mellitus (GDM) are at increased risk of type 2 diabetes (T2DM). However, the time to progression to diabetes differs individually. Objective: We investigated the clinical and
The discovery suggests a new therapeutic target for treating dysfunctional beta cells and type 2 diabetes, a disease affecting more than 25 million Americans. Writing in the April 11, 2013 issue of Cell, Jerrold M. Olefsky, MD, associate dean for
The study, led by Dr. Vivian Fonseca of Tulane's Health Sciences Center, appeared in a February issue of Diabetes Care. It followed 8,929 type 2 patients, approximately half who participated in standard treatment while the other half used more
The Canadian Diabetes Association has released new guidelines that will ensure more people are checked for the disease on a regular basis.